Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.82), $0.13 worse than the analyst estimate of ($0.69). Revenue for the quarter came in at $51.72 million versus the consensus estimate of $55.04 million.

GUIDANCE:

Vanda Pharmaceuticals sees FY2026 revenue of $240-290 million, versus the consensus of $258.2 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.